Li, X., Liang, Y., Qian, W., Xie, Y., Wu, W., Lu, Y. (2026). Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7059